Neurocrine Biosciences’ Post

View organization page for Neurocrine Biosciences, graphic

58,492 followers

Today we announced that the complete study results from the CAHtalyst™ Phase 3 Adult and Pediatric studies have been published in The New England Journal of Medicine (NEJM Group). In addition to being published in the journal, the data were also shared at Endocrine Society 2024. #ENDO2024 https://lnkd.in/g5pRJcnc https://lnkd.in/g_8mvpe5

  • No alternative text description for this image
Anamaria Manea, MD

Board Certified Pediatric Endocrinologist | Physician | Advocate| Assistant Professor of Pediatrics

2w

Great hope for patients with CAH. And exciting news for us endocrinologists! Managing CAH can be so challenging. Crinecerfont is an oral, selective corticotropin-releasing factor type 1 receptor antagonist being investigated to help reduce and control excess adrenal androgens through a steroid-independent mechanism.

Like
Reply

This is great news for such an underserved patient community! 👏👏👏 Amazing work!

Jessica Cella

🚑 💉 EMS Protocol Partner | Rare Disease Advocate | Caregiver | Full time Volunteer

1mo

Exciting times for CAH-ers!! 🙌🏼🙌🏼

Like
Reply

Well done! Congratulations and all the best.

Like
Reply
Arline Nakanishi

Vice President, Biometrics

1mo

Exciting news for Neurocrine and, more importantly, for CAH patients.

Well done Vivian and team! Congratulations!!!

Like
Reply
Jill Harrington

Director Business Development at Aenova Group North America

1mo

Well done!

Like
Reply
Julie Yefchak

Executive Director, Statistical Programming at Neurocrine Biosciences

1mo

Exciting times!

Like
Reply
Nanette L. Styer

Senior Client Manager at Marsh & McLennan Agency - CA License #0H73111

1mo

Impressive!

Like
Reply

Great news!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics